Multivariate analysis of variables associated with clinical failure at day 21 and at end of treatment with piperacillin/tazobactam and mortality at day 30 among patients with bacteraemia due to Enterobacteriaceae
| Variable . | Failure at day 21 . | Failure at end of treatment with piperacillin/tazobactam . | Mortality at day 30 . | |||
|---|---|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Charlson index | 1.30 (1.09–1.55) | <0.01 | 1.14 (0.98–1.33) | 0.09 | 1.36 (1.14–1.63) | <0.001 |
| Pitt score | 1.28 (1.00–1.63) | 0.05 | 1.24 (0.99–1.54) | 0.05 | 1.41 (1.09–1.82) | <0.01 |
| Severe sepsis or septic shock | 2.8 (0.95–8.30) | 0.06 | 2.07 (0.88–4.88) | 0.09 | 3.43 (1.16–10.2) | 0.02 |
| Source in biliary tract | 0.37 (0.13–1.07) | 0.06 | 0.22 (0.53–0.09) | 0.001 | 4.52 (1.44–14.22) | 0.01 |
| Borderline MIC | 0.96 (0.18–4.88) | 0.96 | 0.47 (0.10–2.26) | 0.35 | 1.48 (0.33–6.68) | 0.6 |
| Variable . | Failure at day 21 . | Failure at end of treatment with piperacillin/tazobactam . | Mortality at day 30 . | |||
|---|---|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Charlson index | 1.30 (1.09–1.55) | <0.01 | 1.14 (0.98–1.33) | 0.09 | 1.36 (1.14–1.63) | <0.001 |
| Pitt score | 1.28 (1.00–1.63) | 0.05 | 1.24 (0.99–1.54) | 0.05 | 1.41 (1.09–1.82) | <0.01 |
| Severe sepsis or septic shock | 2.8 (0.95–8.30) | 0.06 | 2.07 (0.88–4.88) | 0.09 | 3.43 (1.16–10.2) | 0.02 |
| Source in biliary tract | 0.37 (0.13–1.07) | 0.06 | 0.22 (0.53–0.09) | 0.001 | 4.52 (1.44–14.22) | 0.01 |
| Borderline MIC | 0.96 (0.18–4.88) | 0.96 | 0.47 (0.10–2.26) | 0.35 | 1.48 (0.33–6.68) | 0.6 |
Multivariate analysis of variables associated with clinical failure at day 21 and at end of treatment with piperacillin/tazobactam and mortality at day 30 among patients with bacteraemia due to Enterobacteriaceae
| Variable . | Failure at day 21 . | Failure at end of treatment with piperacillin/tazobactam . | Mortality at day 30 . | |||
|---|---|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Charlson index | 1.30 (1.09–1.55) | <0.01 | 1.14 (0.98–1.33) | 0.09 | 1.36 (1.14–1.63) | <0.001 |
| Pitt score | 1.28 (1.00–1.63) | 0.05 | 1.24 (0.99–1.54) | 0.05 | 1.41 (1.09–1.82) | <0.01 |
| Severe sepsis or septic shock | 2.8 (0.95–8.30) | 0.06 | 2.07 (0.88–4.88) | 0.09 | 3.43 (1.16–10.2) | 0.02 |
| Source in biliary tract | 0.37 (0.13–1.07) | 0.06 | 0.22 (0.53–0.09) | 0.001 | 4.52 (1.44–14.22) | 0.01 |
| Borderline MIC | 0.96 (0.18–4.88) | 0.96 | 0.47 (0.10–2.26) | 0.35 | 1.48 (0.33–6.68) | 0.6 |
| Variable . | Failure at day 21 . | Failure at end of treatment with piperacillin/tazobactam . | Mortality at day 30 . | |||
|---|---|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Charlson index | 1.30 (1.09–1.55) | <0.01 | 1.14 (0.98–1.33) | 0.09 | 1.36 (1.14–1.63) | <0.001 |
| Pitt score | 1.28 (1.00–1.63) | 0.05 | 1.24 (0.99–1.54) | 0.05 | 1.41 (1.09–1.82) | <0.01 |
| Severe sepsis or septic shock | 2.8 (0.95–8.30) | 0.06 | 2.07 (0.88–4.88) | 0.09 | 3.43 (1.16–10.2) | 0.02 |
| Source in biliary tract | 0.37 (0.13–1.07) | 0.06 | 0.22 (0.53–0.09) | 0.001 | 4.52 (1.44–14.22) | 0.01 |
| Borderline MIC | 0.96 (0.18–4.88) | 0.96 | 0.47 (0.10–2.26) | 0.35 | 1.48 (0.33–6.68) | 0.6 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
